Abstract | BACKGROUND:
Levofloxacin is an effective medication for second line Helicobacter pylori (H. pylori) eradication. However, limited studies have approved its use as an effective antibiotic in first line therapy. Dexlansoprazole is a new PPI and lacks of evidence in support of a role in H. pylori eradication. This study was designed to evaluate efficacy of levofloxacin- dexlansoprazole-based quadruple therapy for H. pylori eradication in Thailand. MATERIALS AND METHODS: RESULTS: A total of 100 patients were enrolled, comprising 44 males and 56 females (mean age of 52.6 years). Eradication rate by PP analysis was 85.7% (42/49) with the 7-day regimen and 98% (48/49) with the 14-day regimen (85.7% vs 98%; p-value=0.059). ITT analysis was 84% and 96% with 7- and 14-day regimens, respectively (84% vs 96%; p-value=0.092). Antibiotic susceptibility testing demonstrated 35.1% resistance to metronidazole, 18.3% to clarithromycin, and 13.5% to levofloxacin. CYP2C19 genotyping revealed 54.1% RM, 34.7% IM and 11.2% PM. The 14-day regimen provided 100% eradication in patients with clarithromycin or dual clarithromycin and metronidazole H. pylori resistant strains. Moreover, the eradication rate was 96.6% in patients with CYP2C19 genotype RM. CONCLUSIONS:
|
Authors | Hatainuch Prapitpaiboon, Varocha Mahachai, Ratha-Korn Vilaichone |
Journal | Asian Pacific journal of cancer prevention : APJCP
(Asian Pac J Cancer Prev)
Vol. 16
Issue 10
Pg. 4353-6
( 2015)
ISSN: 2476-762X [Electronic] Thailand |
PMID | 26028098
(Publication Type: Journal Article, Randomized Controlled Trial)
|
Chemical References |
- Anti-Bacterial Agents
- Antidiarrheals
- Organometallic Compounds
- Proton Pump Inhibitors
- Salicylates
- bismuth subsalicylate
- Levofloxacin
- Cytochrome P-450 CYP2C19
- Clarithromycin
- Bismuth
- Dexlansoprazole
|
Topics |
- Anti-Bacterial Agents
(administration & dosage)
- Antidiarrheals
(administration & dosage)
- Bismuth
(administration & dosage)
- Breath Tests
- Clarithromycin
(administration & dosage)
- Cytochrome P-450 CYP2C19
(genetics)
- Dexlansoprazole
(administration & dosage)
- Drug Therapy, Combination
(adverse effects, methods)
- Female
- Genotype
- Helicobacter Infections
(diagnosis, drug therapy)
- Helicobacter pylori
(genetics)
- Humans
- Intention to Treat Analysis
- Levofloxacin
(administration & dosage)
- Male
- Microbial Sensitivity Tests
- Middle Aged
- Organometallic Compounds
(administration & dosage)
- Prospective Studies
- Proton Pump Inhibitors
(administration & dosage)
- Salicylates
(administration & dosage)
- Thailand
|